Killing all the birds with one drug–is oral roflumilast a novel treatment option for psoriasis?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Psoriasis is a common, chronic inflammatory skin disease associated with a large number of comorbidities. Though management of moderate-to-severe plaque psoriasis has greatly improved in recent years, patients with refractory disease or contraindications to available treatments still constitute therapeutic challenges. Oral roflumilast, a selective phosphodiesterase-4 (PDE-4) inhibitor, is approved for chronic obstructive pulmonary disease. Experimental studies have shown increased PDE-4 activity in psoriatic skin, and inhibition results in down-regulation of key inflammatory cytokines. Based on mode-of-action and available literature, we hypothesize that oral roflumilast is a future treatment for plaque psoriasis. Contrary to most existing psoriasis therapies, roflumilast has a favorable safety profile and holds the potential to improve not only skin manifestations but also commonly seen comorbidities. If efficacy and safety are confirmed in randomized settings, roflumilast can fill in a large unmet need and may represent a novel, relatively inexpensive, and convenient therapy positioned before biologics.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Dermatological Treatment |
Vol/bind | 33 |
Udgave nummer | 6 |
Sider (fra-til) | 2782-2783 |
Antal sider | 2 |
ISSN | 0954-6634 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
M. Gyldenløve: None. A. Egeberg: Research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, and Janssen Pharmaceuticals. Consultant and/or speaker honoraria from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.
Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
ID: 328733995